Learn More About T.E.A.L.

January 30, 2016

Video

Tell Every Amazing Lady's mission is to promote public awareness and education of the signs, symptoms and risk factors of Ovarian Cancer, while providing support to survivors and raising funds for research in order to find the cure for Ovarian Cancer.

Visit www.tealwalk.org for more information about this foundation.

Related Content

Sacituzumab Tirumotecan Shows Promise in Pretreated Gynecologic Cancer

Ashley Chan

November 18th 2024

Article

Sacituzumab tirumotecan had antitumor activity in pretreated advanced endometrial and ovarian cancer, data showed.

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

Lindsay Fischer

June 15th 2023

Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

clinician in white coat holding a board that says "cervical cancer"

Adding Cancer Vaccine to Avelumab Doesn’t Boost PFS in Gynecologic Cancer

Russ Conroy

October 16th 2024

Article

The addition of T4001, an investigation cancer vaccine, to avelumab did not improve progression-free survival vs avelumab alone in cervical and anogenital tumors.

A Look Back at 2022 FDA Approvals in Oncology

Oncology Nursing News

January 2nd 2023

Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

WHO Updates Cervical Cancer Prevention Guidelines

Chris Ryan

October 8th 2024

Article

The World Health Organization updated their guidelines to include CINtec PLUS Cytology for gynecologic cancer prevention.

Dato-DXd Seems Safe, Efficacious in Advanced Gynecologic Cancers

Jason M. Broderick

September 18th 2024

Article

Datopotamab deruxtecan(Dato-DXd) demonstrated antitumor activity in patients with advanced/metastatic ovarian or endometrial cancer who had prior chemotherapy treatment.

Related Content

Sacituzumab Tirumotecan Shows Promise in Pretreated Gynecologic Cancer

Ashley Chan

November 18th 2024

Article

Sacituzumab tirumotecan had antitumor activity in pretreated advanced endometrial and ovarian cancer, data showed.

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

Lindsay Fischer

June 15th 2023

Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Adding Cancer Vaccine to Avelumab Doesn’t Boost PFS in Gynecologic Cancer

Russ Conroy

October 16th 2024

Article

The addition of T4001, an investigation cancer vaccine, to avelumab did not improve progression-free survival vs avelumab alone in cervical and anogenital tumors.

A Look Back at 2022 FDA Approvals in Oncology

Oncology Nursing News

January 2nd 2023

Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

WHO Updates Cervical Cancer Prevention Guidelines

Chris Ryan

October 8th 2024

Article

The World Health Organization updated their guidelines to include CINtec PLUS Cytology for gynecologic cancer prevention.

Dato-DXd Seems Safe, Efficacious in Advanced Gynecologic Cancers

Jason M. Broderick

September 18th 2024

Article

Datopotamab deruxtecan(Dato-DXd) demonstrated antitumor activity in patients with advanced/metastatic ovarian or endometrial cancer who had prior chemotherapy treatment.